NuVasive Inc
NASDAQ:NUVA
Intrinsic Value
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. [ Read More ]
The intrinsic value of one NUVA stock under the Base Case scenario is 58.81 USD. Compared to the current market price of 39.75 USD, NuVasive Inc is Undervalued by 32%.
Valuation Backtest
NuVasive Inc
Run backtest to discover the historical profit from buying and selling NUVA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
NuVasive Inc
Current Assets | 728.3m |
Cash & Short-Term Investments | 80.7m |
Receivables | 267.1m |
Other Current Assets | 380.4m |
Non-Current Assets | 1.4B |
PP&E | 452.6m |
Intangibles | 808.3m |
Other Non-Current Assets | 100.4m |
Current Liabilities | 582.6m |
Accounts Payable | 118.8m |
Accrued Liabilities | 60.7m |
Short-Term Debt | 350m |
Other Current Liabilities | 53.1m |
Non-Current Liabilities | 614.4m |
Long-Term Debt | 446.4m |
Other Non-Current Liabilities | 168m |
Earnings Waterfall
NuVasive Inc
Revenue
|
1.2B
USD
|
Cost of Revenue
|
-347.5m
USD
|
Gross Profit
|
878.7m
USD
|
Operating Expenses
|
-796.2m
USD
|
Operating Income
|
82.6m
USD
|
Other Expenses
|
-54.1m
USD
|
Net Income
|
28.5m
USD
|
Free Cash Flow Analysis
NuVasive Inc
What is Free Cash Flow?
NUVA Profitability Score
Profitability Due Diligence
NuVasive Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
NuVasive Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
NUVA Solvency Score
Solvency Due Diligence
NuVasive Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
NuVasive Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NUVA Price Targets Summary
NuVasive Inc
According to Wall Street analysts, the average 1-year price target for NUVA is 45 USD .
Ownership
NUVA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NUVA Price
NuVasive Inc
Average Annual Return | 0.92% |
Standard Deviation of Annual Returns | 31.52% |
Max Drawdown | -60% |
Market Capitalization | 2.1B USD |
Shares Outstanding | 52 449 200 |
Percentage of Shares Shorted | 15.59% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. The company is headquartered in San Diego, California and currently employs 2,900 full-time employees. The company went IPO on 2004-05-13. The firm offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for spine and specialized orthopedic procedures. In addition, it also designs and sells expandable growing rod implant systems for the treatment of early-onset scoliosis, which can be non-invasively lengthened implantation with precise, incremental adjustments via an external remote controller using magnetic technology called MAGnetic External Control (MAGEC).
Contact
IPO
Employees
Officers
The intrinsic value of one NUVA stock under the Base Case scenario is 58.81 USD.
Compared to the current market price of 39.75 USD, NuVasive Inc is Undervalued by 32%.